Heart Test Laboratories, Inc. (HSCS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.2400 |
| Open | 2.2500 |
| Bid | 1.9000 x 2200 |
| Ask | 2.0900 x 1000 |
| Day's Range | 1.9900 - 2.8700 |
| 52 Week Range | 1.1500 - 6.0000 |
| Volume | |
| Avg. Volume | 1,718,342 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results
MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year Completed IPO in June 2022 with Approximately $6.375M of Gross Proceeds Listed on NASDAQ Capital Market under Ticker HSCS Southlake, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) -- – Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve a
- GlobeNewswire
HeartSciences CEO to Participate in the Benzinga All Access Event on July 15th
Southlake, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- HeartSciences (NASDAQ: HSCS; HSCSW) (“Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness, today announced that Andrew Simpson, CEO, and Chairman of HeartSciences, will be participating in the Benzinga All Access event taking place on July 15, 2022. Mr. Simpson is scheduled to present on Friday, July 15, 2022,
- GlobeNewswire
Heart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing
SOUTHLAKE, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness, today announced the pricing of its initial public offering of 1,500,000 units, each consisting of one share of common stock (the “Common Stock”) and a warrant (the “Warrants”) to purchase one sha
